ECSP066959A - MACROCICLICAL COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION - Google Patents
MACROCICLICAL COMPOUNDS AS INHIBITORS OF VIRAL REPLICATIONInfo
- Publication number
- ECSP066959A ECSP066959A EC2006006959A ECSP066959A ECSP066959A EC SP066959 A ECSP066959 A EC SP066959A EC 2006006959 A EC2006006959 A EC 2006006959A EC SP066959 A ECSP066959 A EC SP066959A EC SP066959 A ECSP066959 A EC SP066959A
- Authority
- EC
- Ecuador
- Prior art keywords
- compounds
- methods
- macrociclical
- inhibitors
- viral replication
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
En diversas realizaciones se proveen compuestos de las Fórmulas generales I-XIX, así como composiciones, entre las que se incluyen composiciones farmacéuticas, que comprenden un compuesto de la invención. Las realizaciones proveen además métodos de tratamiento, que incluyen métodos de tratamiento de infecciones flavivirales, que incluyen la infección por el virus de hepatitis C y métodos de tratar la fibrosis hepática. Los métodos consisten en general en la administración a un individuo que lo necesita, una cantidad eficaz de un compuesto o composición de la invención.In various embodiments, compounds of General Formulas I-XIX are provided, as well as compositions, including pharmaceutical compositions, which comprise a compound of the invention. The embodiments further provide treatment methods, which include methods of treating flaviviral infections, which include hepatitis C virus infection and methods of treating liver fibrosis. The methods generally consist of administering to an individual in need, an effective amount of a compound or composition of the invention.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55816104P | 2004-03-30 | 2004-03-30 | |
US56241804P | 2004-04-14 | 2004-04-14 | |
US61238104P | 2004-09-22 | 2004-09-22 | |
US61246004P | 2004-09-22 | 2004-09-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP066959A true ECSP066959A (en) | 2006-12-20 |
Family
ID=35005653
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2006006959A ECSP066959A (en) | 2004-03-30 | 2006-10-27 | MACROCICLICAL COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP1749007A2 (en) |
JP (1) | JP4950026B2 (en) |
AP (1) | AP2006003763A0 (en) |
AR (1) | AR050321A1 (en) |
AU (1) | AU2005228894B9 (en) |
BR (1) | BRPI0509467A (en) |
CA (1) | CA2560897C (en) |
CU (1) | CU23787B7 (en) |
EA (1) | EA012389B1 (en) |
EC (1) | ECSP066959A (en) |
GE (1) | GEP20104926B (en) |
IL (1) | IL177917A0 (en) |
MA (1) | MA28548B1 (en) |
NO (1) | NO20064933L (en) |
NZ (1) | NZ549697A (en) |
WO (1) | WO2005095403A2 (en) |
Families Citing this family (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
JP5007226B2 (en) | 2004-07-15 | 2012-08-22 | エーエムアール テクノロジー インコーポレイテッド | Aryl and heteroaryl substituted tetrahydroisoquinolines and their use to block reuptake of norepinephrine, dopamine, and serotonin |
US7323447B2 (en) | 2005-02-08 | 2008-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP1863833B1 (en) * | 2005-03-08 | 2013-09-18 | Boehringer Ingelheim International GmbH | Process for preparing macrocyclic compounds |
US7592336B2 (en) | 2005-05-10 | 2009-09-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7601686B2 (en) | 2005-07-11 | 2009-10-13 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7470664B2 (en) | 2005-07-20 | 2008-12-30 | Merck & Co., Inc. | HCV NS3 protease inhibitors |
EP2305697A3 (en) | 2005-07-25 | 2011-07-27 | Intermune, Inc. | Macrocyclic inhibitors of Hepatitis C virus replication |
PL1919898T3 (en) * | 2005-07-29 | 2011-06-30 | Tibotec Pharm Ltd | Macrocyclic inhibitors of hepatitis c virus |
AR055395A1 (en) | 2005-08-26 | 2007-08-22 | Vertex Pharma | INHIBITING COMPOUNDS OF THE ACTIVITY OF SERINA PROTEASA NS3-NS4A OF HEPATITIS C VIRUS |
US7772183B2 (en) * | 2005-10-12 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7741281B2 (en) | 2005-11-03 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
CA2634743C (en) | 2005-12-23 | 2014-07-29 | Zealand Pharma A/S | Modified lysine-mimetic compounds |
EP2049474B1 (en) | 2006-07-11 | 2015-11-04 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
EA017448B1 (en) | 2006-07-13 | 2012-12-28 | Ачиллион Фармасьютикалз, Инк. | 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication |
US8343477B2 (en) | 2006-11-01 | 2013-01-01 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
US7772180B2 (en) | 2006-11-09 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
ES2357494T3 (en) * | 2006-11-16 | 2011-04-27 | Bristol-Myers Squibb Company | MACROCYCLIC PEPTIDES AS INHIBITORS OF HEPATITIS C. |
US7888464B2 (en) | 2006-11-16 | 2011-02-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8003604B2 (en) | 2006-11-16 | 2011-08-23 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7763584B2 (en) * | 2006-11-16 | 2010-07-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP2468724B1 (en) | 2006-12-21 | 2015-11-18 | Zealand Pharma A/S | Synthesis of pyrrolidine compounds |
KR20090101372A (en) * | 2007-01-08 | 2009-09-25 | 페노믹스 코포레이션 | Macrocyclic hepatitis c protease inhibitors |
WO2008096002A1 (en) * | 2007-02-08 | 2008-08-14 | Tibotec Pharmaceuticals Ltd. | Hcv inhibiting macrocyclic phosphonates and amidophosphates |
US8435984B2 (en) | 2007-02-26 | 2013-05-07 | Achillion Pharmaceuticals, Inc. | Tertiary amine substituted peptides useful as inhibitors of HCV replication |
US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
NZ581606A (en) * | 2007-05-03 | 2012-06-29 | Intermune Inc | Novel macrocyclic inhibitors of hepatitis c virus replication |
WO2009005690A2 (en) * | 2007-06-29 | 2009-01-08 | Gilead Sciences, Inc. | Antiviral compounds |
MX2009013827A (en) * | 2007-06-29 | 2010-03-01 | Gilead Sciences Inc | Antiviral compounds. |
AP2009005073A0 (en) | 2007-06-29 | 2009-12-31 | Gilead Sciences Inc | Antiviral compounds |
SE531698C2 (en) | 2007-07-12 | 2009-07-07 | Respiratorius Ab | New bronchodilating a, b unsaturated amides |
US8293705B2 (en) | 2007-12-21 | 2012-10-23 | Avila Therapeutics, Inc. | HCV protease inhibitors and uses thereof |
US8202996B2 (en) | 2007-12-21 | 2012-06-19 | Bristol-Myers Squibb Company | Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide |
CA2710144A1 (en) | 2007-12-21 | 2009-07-02 | Avila Therapeutics, Inc. | Hcv protease inhibitors and uses thereof |
NZ586231A (en) | 2007-12-21 | 2012-12-21 | Avila Therapeutics Inc | HCV protease inhibitors comprising a functionalised proline derivative |
US8309685B2 (en) | 2007-12-21 | 2012-11-13 | Celgene Avilomics Research, Inc. | HCV protease inhibitors and uses thereof |
CN101910177B (en) * | 2007-12-24 | 2013-08-28 | 泰博特克药品公司 | Macrocyclic indoles as hepatitis C virus inhibitors |
MX2010010660A (en) * | 2008-04-11 | 2010-10-25 | Hoffmann La Roche | New ruthenium complexes as catalysts for metathesis reactions. |
US8163921B2 (en) | 2008-04-16 | 2012-04-24 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7964560B2 (en) | 2008-05-29 | 2011-06-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
JP5529120B2 (en) | 2008-05-29 | 2014-06-25 | ブリストル−マイヤーズ スクイブ カンパニー | Hepatitis C virus inhibitor |
US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
BRPI0916609A2 (en) * | 2008-08-07 | 2015-08-04 | Hoffmann La Roche | Process for the preparation of a macrocycle |
US8207341B2 (en) | 2008-09-04 | 2012-06-26 | Bristol-Myers Squibb Company | Process or synthesizing substituted isoquinolines |
UY32099A (en) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | HEPATITIS C SERINA PROTEASAS MACROCYCLIC INHIBITORS |
WO2010033443A1 (en) | 2008-09-17 | 2010-03-25 | Boehringer Ingelheim International Gmbh | Combination of hcv ns3 protease inhibitor with interferon and ribavirin |
US8044087B2 (en) | 2008-09-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8563505B2 (en) | 2008-09-29 | 2013-10-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
PL2364309T3 (en) | 2008-12-10 | 2015-03-31 | Achillion Pharmaceuticals Inc | New 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication |
US8283310B2 (en) | 2008-12-15 | 2012-10-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8551973B2 (en) | 2008-12-23 | 2013-10-08 | Gilead Pharmasset Llc | Nucleoside analogs |
US8716263B2 (en) | 2008-12-23 | 2014-05-06 | Gilead Pharmasset Llc | Synthesis of purine nucleosides |
EP3222628A1 (en) | 2008-12-23 | 2017-09-27 | Gilead Pharmasset LLC | Nucleoside phosphoramidates |
DK2401272T3 (en) | 2009-02-27 | 2017-02-27 | Janssen Pharmaceuticals Inc | AMORF SALT OF A MACROCYCLIC INHIBITOR OF HCV |
CA2758072A1 (en) | 2009-04-08 | 2010-10-14 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
CN102458123A (en) | 2009-05-12 | 2012-05-16 | 阿尔巴尼分子研究公司 | Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof |
KR101830447B1 (en) | 2009-05-12 | 2018-02-20 | 알바니 몰레큘라 리써치, 인크. | 7-([1,2,4]TRIAZOLO[1,5-α]PYRIDIN-6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF |
JP5739415B2 (en) | 2009-05-12 | 2015-06-24 | ブリストル−マイヤーズ スクウィブ カンパニー | (S) -7-([1,2,4] triazolo [1,5-a] pyridin-6-yl) -4- (3,4-dichlorophenyl) -1,2,3,4-tetrahydroisoquinoline Crystal forms and uses thereof |
TWI576352B (en) | 2009-05-20 | 2017-04-01 | 基利法瑪席特有限責任公司 | Nucleoside phosphoramidates |
US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
US8232246B2 (en) | 2009-06-30 | 2012-07-31 | Abbott Laboratories | Anti-viral compounds |
PL2451438T3 (en) | 2009-07-07 | 2014-07-31 | Boehringer Ingelheim Int | Pharmaceutical composition for a hepatitis c viral protease inhibitor |
WO2011017389A1 (en) | 2009-08-05 | 2011-02-10 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv |
MX2012003171A (en) * | 2009-09-28 | 2012-04-11 | Hoffmann La Roche | Novel macrocyclic inhibitors of hepatitis c virus replication. |
CN102596201A (en) | 2009-10-30 | 2012-07-18 | 贝林格尔.英格海姆国际有限公司 | Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin |
US8933110B2 (en) | 2010-01-25 | 2015-01-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
BR112012018529A2 (en) | 2010-01-25 | 2016-08-09 | Enanta Pharm Inc | hepatitis c virus inhibitors, their pharmaceutical composition and their use, and method for inhibiting replication of an rna-containing virus |
PT3290428T (en) | 2010-03-31 | 2021-12-27 | Gilead Pharmasset Llc | Tablet comprising crystalline (s)-isopropyl 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1 (2h)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate |
UY33312A (en) | 2010-03-31 | 2011-10-31 | Pharmasset Inc | PURINE NUCLEOSIDE PHOSPHORAMIDATE |
EP2455068A1 (en) * | 2010-11-09 | 2012-05-23 | F. Hoffmann-La Roche AG | Pharmaceutical composition for treating HCV infections |
SG10202010119TA (en) | 2010-11-15 | 2020-11-27 | Abbvie Inc | NAMPT And Rock Inhibitors |
AU2011336632B2 (en) | 2010-11-30 | 2015-09-03 | Gilead Pharmasset Llc | Compounds |
US8951964B2 (en) | 2010-12-30 | 2015-02-10 | Abbvie Inc. | Phenanthridine macrocyclic hepatitis C serine protease inhibitors |
EP2658859A4 (en) | 2010-12-30 | 2014-07-30 | Enanta Pharm Inc | Macrocyclic hepatitis c serine protease inhibitors |
TW201309690A (en) | 2011-02-10 | 2013-03-01 | Idenix Pharmaceuticals Inc | Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections |
US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
GB201116559D0 (en) | 2011-09-26 | 2011-11-09 | Univ Leuven Kath | Novel viral replication inhibitors |
US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
WO2013185284A1 (en) | 2012-06-12 | 2013-12-19 | Abbott Laboratories | Pyridinone and pyridazinone derivatives |
BR112015007879A2 (en) | 2012-10-19 | 2017-07-04 | Bristol Myers Squibb Co | hepatitis c virus inhibitors |
EP2914598B1 (en) | 2012-11-02 | 2017-10-18 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
EP2914613B1 (en) | 2012-11-02 | 2017-11-22 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP2914614B1 (en) | 2012-11-05 | 2017-08-16 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
JP6342922B2 (en) | 2013-03-07 | 2018-06-13 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Hepatitis C virus inhibitor |
JP2016515139A (en) | 2013-03-14 | 2016-05-26 | アキリオン ファーマシューティカルズ,インコーポレーテッド | A new method for producing buckwheatprevir |
WO2014145600A1 (en) | 2013-03-15 | 2014-09-18 | Achillion Pharmaceuticals, Inc. | Ach-0142684 sodium salt polymorphs, composition including the same, and method of manufacture thereof |
US9006423B2 (en) | 2013-03-15 | 2015-04-14 | Achillion Pharmaceuticals Inc. | Process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof |
BR112015023351A2 (en) | 2013-03-15 | 2017-07-18 | Achillion Pharmaceuticals Inc | crystalline form of sovaprevir, pharmaceutical composition, and method for treating a disorder |
EP4005560A1 (en) | 2013-08-27 | 2022-06-01 | Gilead Pharmasset LLC | Combination formulation of two antiviral compounds |
EP3089757A1 (en) | 2014-01-03 | 2016-11-09 | AbbVie Inc. | Solid antiviral dosage forms |
US11324799B2 (en) | 2017-05-05 | 2022-05-10 | Zealand Pharma A/S | Gap junction intercellular communication modulators and their use for the treatment of diabetic eye disease |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6323180B1 (en) * | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
AR022061A1 (en) * | 1998-08-10 | 2002-09-04 | Boehringer Ingelheim Ca Ltd | INHIBITING PEPTIDES OF HEPATITIS C, A PHARMACEUTICAL COMPOSITION CONTAINING THEM, THE USE OF THE SAME TO PREPARE A PHARMACEUTICAL COMPOSITION, THE USE OF AN INTERMEDIATE PRODUCT FOR THE PREPARATION OF THESE PEPTIDES AND A PROCEDURE FOR THE PREPARATION OF ANOGRAPH . |
UA74546C2 (en) * | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
US6608027B1 (en) * | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
AU2002248147B2 (en) * | 2000-11-20 | 2006-04-06 | Bristol-Myers Squibb Company | Hepatitis C tripeptide inhibitors |
US6867185B2 (en) * | 2001-12-20 | 2005-03-15 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
CA2369711A1 (en) * | 2002-01-30 | 2003-07-30 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis c virus |
CA2369970A1 (en) * | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
CA2370396A1 (en) * | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
US6828301B2 (en) * | 2002-02-07 | 2004-12-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for hepatitis C viral protease inhibitors |
MY140680A (en) * | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
ES2350201T3 (en) * | 2002-05-20 | 2011-01-20 | Bristol-Myers Squibb Company | HETEROCYCLIC SULPHAMIDES AS INHIBITORS OF HEPATITIS C VIRUS. |
CA2540858C (en) * | 2003-10-14 | 2009-12-08 | Intermune, Inc. | Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication |
US7608590B2 (en) * | 2004-01-30 | 2009-10-27 | Medivir Ab | HCV NS-3 serine protease inhibitors |
-
2005
- 2005-03-29 AU AU2005228894A patent/AU2005228894B9/en not_active Ceased
- 2005-03-29 AP AP2006003763A patent/AP2006003763A0/en unknown
- 2005-03-29 NZ NZ549697A patent/NZ549697A/en not_active IP Right Cessation
- 2005-03-29 BR BRPI0509467-4A patent/BRPI0509467A/en not_active IP Right Cessation
- 2005-03-29 EP EP05757750A patent/EP1749007A2/en not_active Withdrawn
- 2005-03-29 JP JP2007506466A patent/JP4950026B2/en not_active Expired - Fee Related
- 2005-03-29 EA EA200601467A patent/EA012389B1/en not_active IP Right Cessation
- 2005-03-29 GE GEAP20059674A patent/GEP20104926B/en unknown
- 2005-03-29 CA CA2560897A patent/CA2560897C/en not_active Expired - Fee Related
- 2005-03-29 WO PCT/US2005/010494 patent/WO2005095403A2/en active Application Filing
- 2005-03-30 AR ARP050101257A patent/AR050321A1/en not_active Application Discontinuation
-
2006
- 2006-09-06 IL IL177917A patent/IL177917A0/en unknown
- 2006-10-20 MA MA29407A patent/MA28548B1/en unknown
- 2006-10-27 NO NO20064933A patent/NO20064933L/en not_active Application Discontinuation
- 2006-10-27 EC EC2006006959A patent/ECSP066959A/en unknown
-
2009
- 2009-12-08 CU CU20090209A patent/CU23787B7/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
NO20064933L (en) | 2006-12-15 |
GEP20104926B (en) | 2010-03-25 |
CU23787B7 (en) | 2012-03-15 |
AP2006003763A0 (en) | 2006-10-31 |
AU2005228894B2 (en) | 2011-08-25 |
JP2007531749A (en) | 2007-11-08 |
WO2005095403A2 (en) | 2005-10-13 |
AR050321A1 (en) | 2006-10-18 |
EA200601467A1 (en) | 2007-06-29 |
CA2560897C (en) | 2012-06-12 |
WO2005095403A3 (en) | 2005-12-01 |
EP1749007A2 (en) | 2007-02-07 |
IL177917A0 (en) | 2006-12-31 |
EA012389B1 (en) | 2009-10-30 |
MA28548B1 (en) | 2007-04-03 |
BRPI0509467A (en) | 2007-09-11 |
CU20090209A7 (en) | 2011-04-26 |
CA2560897A1 (en) | 2005-10-13 |
JP4950026B2 (en) | 2012-06-13 |
AU2005228894A1 (en) | 2005-10-13 |
NZ549697A (en) | 2009-12-24 |
AU2005228894B9 (en) | 2011-10-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP066959A (en) | MACROCICLICAL COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | |
CU20090112A6 (en) | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | |
AR055095A1 (en) | NEW MACROCICLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | |
ECSP066570A (en) | MACROCYCLIC AND ACILSULPHONAMID CARBOXYLIC ACIDS AS HCV REPLICATION INHIBITORS | |
NI200900205A (en) | NEW INHIBITOR PEPTIDES OF THE REPLICATION OF THE HEPATITIS C VIRUS. | |
ECSP099780A (en) | NEW MACROCICLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | |
CO6321290A2 (en) | NEW MACROCICLIC INHIBITORS BASED ON PIRROLIDINYL OF THE VIRUS REPLICATION OF HEPATITIS C | |
UY29266A1 (en) | PIRIDAZINONA COMPOUNDS | |
UY29868A1 (en) | NUCLEOCIDOS 4 MODIFIED AS ANTIVIRAL AGENTS | |
WO2007047146A3 (en) | Inhibitors of viral replication | |
ECSP077412A (en) | TETRACYCLIC INDOL DERIVATIVES AS ANTI-AGENT AGENTS | |
BRPI0514176A (en) | hcv replication inhibitors | |
EA200800178A1 (en) | HEPATITIS C VIRUS INHIBITORS (HCV) | |
BRPI0418251C1 (en) | phosphonates, monophosphonamidates, bisphosphonamidates, and pharmaceutical composition comprising them | |
BRPI0517463A (en) | hepatitis c virus protease inhibitors, compositions and treatments using the same | |
SV2005001920A (en) | "NUCLEOSID COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTIONS" | |
AR030591A1 (en) | PEPTIDOMIMETIC PROTEASA INHIBITORS | |
EA200700718A1 (en) | COMBINED ANTI-VIRAL COMPOSITIONS CONTAINING KASTANOSPERMIN AND METHODS OF THEIR APPLICATION | |
SV2005001919A (en) | NUCLEOSID COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTIONS | |
CU23602A3 (en) | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | |
CU20090182A7 (en) | NEW MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | |
TW200611905A (en) | Macrocyclic compounds as inhibitors of viral replication | |
CU20090188A7 (en) | NEW INHIBITING PEPTIDES OF HEPATITIS C VIRUS REPLICATION | |
UA95455C2 (en) | Macrocyclic inhibitors of hepatitis c virus replication |